BioWorks Inc. Overview
BioWorks, Inc. is a North American developer, manufacturer and marketer of biological crop protection and plant health inputs. Its base is greenhouse ornamentals, nursery, controlled-environment vegetables, cannabis and, increasingly, outdoor specialty crops. The company grew out of Cornell University Trichoderma research and built its franchise on the RootShield biofungicide family. It has since broadened into foliar disease control, bioinsecticides, beneficial nematodes, soaps and oils, a bioherbicide, and a fast-growing plant nutrition and biostimulant line. BioWorks sells through horticultural distributors and supports growers with a technical field team, which is a real differentiator in a category where correct use determines results. Since July 2023 it has belonged to Biobest/BioFirst Group, the biologicals arm of Floridienne. It now serves as the group's North American biopesticide manufacturing hub, with plans to export Trichoderma output to Brazil and Europe. Management's stated ambition is USD 100 million of BioWorks revenue by 2034.
What the company does. BioWorks formulates, produces, registers and sells biologically based inputs that prevent or control plant diseases and insect, mite and nematode pests, plus products that support plant nutrition and stress tolerance. Its current self-description (press releases, 2026) is a leading provider of biological crop protection and plant health solutions. The "About BioWorks" boilerplate in the August 2026 BIOTROP release calls it a North American leader in biological solutions for horticulture, greenhouse and specialty crop markets, supplying biopesticides and biostimulants that reduce reliance on conventional chemistry. There is no annual report to quote from, because the company does not publish one.
Business model. The model is a branded specialty-input manufacturer with a technical-sales overlay. Three elements define it:
-
Proprietary and licensed actives. The core asset is the Cornell-derived Trichoderma harzianum strain T-22 (RootShield), later combined with T. virens G-41 (RootShield PLUS). Several other products rely on third-party actives or strains (for example CEASE, based on Bacillus subtilis QST 713). Licensing terms are not disclosed.
-
In-house manufacturing and formulation. The Victor facility (over 55,000 sq ft) combines production, R&D, warehouse and office functions (Biobest releases, 2023).
-
Distributor channel. Products reach growers through horticultural and agricultural distributors in the US, Canada and Mexico; the website lists "Where to Buy" directories for all three. From September 2025, European distributors buy BioWorks-branded products directly from BioWorks (New AG International, 19 Sep 2025).
Revenue model. Revenue is product sales. There is no disclosed subscription, licensing or service revenue. Technical support, webinars and program design are bundled with product rather than billed. The product/service/licensing mix is not publicly disclosed.
Value chain position. BioWorks sits between strain and technology originators (universities, licensors, sister company BIOTROP) and distributors. It carries the regulatory burden (US EPA FIFRA registrations, state registrations, PMRA in Canada, OMRI listings for organic use), which is a meaningful barrier to entry.
Customers and end-markets. The website's own segmentation of grower types is: indoor horticulture, indoor vegetable, nursery, outdoor specialty agriculture, and cannabis. The February 2026 strategy statement names grapes, almonds and berries as open-field targets.
Independent characterization. BioWorks is a small, technically credible niche player with a strong brand in US greenhouse ornamentals. For three decades it was run as an independent company with steady growth (RBJ reported revenue growth of 27% in 2010, 23% in 2011 and 10% in 2012; a 2018 Western Growers profile described double-digit annual growth). Its strategic meaning has changed since 2023. It is now the North American horticulture channel and Trichoderma production site for a group whose centre of gravity is Brazilian row-crop biologicals. That brings a much larger technology pipeline, and the 2026 launch cadence shows it. It also means BioWorks' priorities are now set in Brazil and Belgium, not in Victor.
Strategy
Stated strategy. Management's February 2026 statement set out six priorities for the next phase (paraphrased from the release):
-
Strengthen leadership in horticulture and greenhouse crops.
-
Expand into open-field specialty crops such as grapes, almonds and berries.
-
Accelerate revenue growth through disciplined commercial execution.
-
Broaden national sales coverage across the United States.
-
Scale operations to support a larger portfolio.
-
Bring BIOTROP's proprietary biological technologies to the US market.
Chris Rose framed the transition as "an acceleration", not a reset.
Initiatives, last 24 months.
Medium-term targets.
Sustainability commitments. None are published by BioWorks. At group level Biobest stated an aim of CO2 neutrality from 2026 (Floridienne Annual Report 2023). No cost-reduction programs with targets have been disclosed.
Products & Services
The catalogue below follows the US product navigation on bioworksinc.com as of September 2026. Pricing is set through distributors and is not publicly disclosed for any product.
Disease Control
| Product | Description and capability | Target customer | Launch / status |
|---|---|---|---|
| RootShield (WP, Granules) | Preventive biofungicide for root diseases based on Trichoderma harzianum strain T-22; colonizes roots. Founding product from Cornell technology | Greenhouse, nursery, vegetable transplant growers | Trademark filed 1996; flagship |
| RootShield PLUS (WP, Granules) | Two-strain formulation adding Trichoderma virens G-41 for broader root pathogen coverage, including warm-season Pythium | Same, plus nursery container production (2026 boxwood trial with Everde Growers) | Established by 2018 |
| BotryStop WP | Biofungicide for Botrytis and related foliar and flower pathogens (Ulocladium oudemansii U3; analyst knowledge) | Ornamentals, berries, grapes, cannabis | Pre-2023 |
| CEASE | Broad-spectrum foliar and soil biofungicide and bactericide based on Bacillus subtilis QST 713; OMRI listed; tank-mix partner with MilStop | Greenhouse ornamentals and vegetables | Long-standing |
| MilStop SP | Potassium bicarbonate contact fungicide, curative on powdery mildew; OMRI listed | Greenhouse, nursery, cannabis | Long-standing; SP is the current formulation |
| PERpose Plus | Peroxide-based broad-spectrum sanitizer and fungicide (analyst knowledge) | Greenhouse | Pre-2023 |
| Sandrine | Copper soap fungicide and bactericide | Horticulture and specialty crops | Launched Feb 2026 |
Pest Control
| Product | Description and capability | Target customer | Launch / status |
|---|---|---|---|
| PRINCIPLE WP | Broad-spectrum bioinsecticide based on Beauveria bassiana; developed in-house from grower feedback; replaces the BotaniGard/Mycotrol slot lost in 2022 | Greenhouse and specialty crops | 2,025 |
| BioNex | Pest control product | — | Launched H1 2026 |
| Cintro | Insecticidal soap | Horticulture | Launched Feb 2026 |
| EpiShield O | Pest control product | — | Listed 2026 |
| Molt-X | Azadirachtin-based insect growth regulator (analyst knowledge) | Greenhouse, nursery | Long-standing |
| NemaShield | Beneficial nematodes, Steinernema feltiae, for fungus gnats and thrips pupae (analyst knowledge) | Greenhouse | Pre-2023 |
| NemaShield HB | Beneficial nematodes, Heterorhabditis bacteriophora, for soil grubs and weevils (analyst knowledge) | Nursery, turf | Pre-2023 |
| SuffOil-X | Pre-emulsified light horticultural oil for soft-bodied insects and mites, with suppression of some foliar diseases | Greenhouse, nursery | Long-standing |
| TotalNema Ax | FIFRA 25(b) botanical nematicide against plant-parasitic nematodes | Outdoor specialty crops | Launched 15 May 2026 |
| Sticky Cards | Monitoring and mass-trapping cards | Greenhouse | Accessory |
Herbicide
| Product | Description | Launch / status |
|---|---|---|
| Hoplite | BioWorks' first herbicide entry | Launched H1 2026 |
Plant Nutrition and Biostimulants
| Product | Description | Launch / status |
|---|---|---|
| ON-Gard | Plant-derived nutritional biostimulant (protein hydrolysate; analyst knowledge) | In portfolio since at least 2015 |
| R.S.S.I. | Plant nutrition product | Listed 2026 |
| GreenSpring | Mixed-mineral fertilizer for root initiation and early development; designed to fit IPM programs | Launched 10 Jul 2026 |
| Stemmer | Highly soluble silicon product for cell wall strength, nutrient and water use efficiency | Launched 4 Aug 2026 |
| BioRain Ax | Microbial inoculant to mitigate limited-water stress and support yield | Launched 3 Sep 2026 |
Canada catalogue
The Canadian range is narrower because of separate PMRA registration: RootShield, MilStop, SuffOil-X and ON-Gard.
Discontinued or transferred
| Product | Status |
|---|---|
| BotaniGard (22WP, ES, MAXX) and Mycotrol (WPO, ESO) | Distributed by BioWorks until September 2022; returned to manufacturer Certis Biologicals |
| Verdanta fertilizers | In portfolio in 2015–2018; absent from the 2026 catalogue |
| RootMate, TopShield | Historical trademarks and labels; not in the current catalogue |
Services
Technical services (program design, compatibility guidance with beneficial insects, webinars, a knowledge base and trial work) are provided free of charge as sales support. Named technical leaders include Dr. Michael Brownbridge (Senior Technical Services Manager) and Carlos E. Bográn (Director of Technical Services).
Financial Narrative
BioWorks, Inc. standalone. Revenue, gross profit, operating income, EBITDA, net income, balance sheet, cash flow and all ratios are not publicly disclosed. As an unlisted subsidiary it publishes no financial statements, and Floridienne does not break out BioWorks in its segment note. The acquisition price paid by Biobest in 2023 was also not disclosed. The only quantitative markers in the public record are:
Parent context: Floridienne S.A. consolidated (EUR millions, IFRS). Source: Annual Report 2025 five-year summary and annual results releases.
Revenue CAGR FY2021–FY2025: about 19.7% (calculated).
Parent context: Life Sciences Division, which contains BioFirst and BioWorks (EUR millions).
Half-year series, Life Sciences Division (EUR millions).
H1 2026 results would normally have been published in late September 2026.
Data flags.
-
Group EBITDA of EUR 116.8 million for FY2024 comes from a secondary source and was not confirmed against the filing. Group EBITDA for other years was not captured.
-
The FY2024 net result attributable to Floridienne appears as 16.07 in the FY2024 release and 15.7 in the Annual Report 2025 summary. Both are shown here; the later figure may reflect a restatement.
-
Earnings per share: the H1 2025 report shows basic EPS of EUR -6.48 (H1 2024: EUR 1.35). Test-Achats (June 2026) cites FY2025 EPS of EUR 0.81, which is inconsistent with a group-share result of EUR 8.0 million on the historical share count unless the share count changed.
-
No estimates are substituted.
Commentary. Three points matter for a reader interested in BioWorks.
First, the group that owns BioWorks changed shape in a single transaction. Life Sciences revenue rose 41.1% in FY2024 and EBITDA more than doubled, and almost all of that is BIOTROP's consolidation. The historical greenhouse business (Biobest, BioWorks, Plant Products) is described by Floridienne as performing well in 2024 on sustained demand and production efficiency, but it is now the smaller part of the division.
Second, profitability softened in 2025. Division EBITDA fell EUR 6.8 million to EUR 95.4 million despite higher sales, and the H1 2025 report attributes the first-half decline mainly to keener competition. Group net result halved, with Floridienne citing unfavourable currency trends; Test-Achats also points to higher amortization and Turkish hyperinflation accounting. A BRL-exposed, leveraged parent with compressing margins has less room to fund subsidiaries generously.
Third, 2023 was a weak year for Biobest's legacy business (Floridienne called it disappointing, citing external factors), which is the period in which BioWorks was acquired. BioWorks was bought into a trough and has since been run through a recovery and then a leadership change.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Level | Entity | Role |
|---|---|---|
Listed parent | Floridienne S.A. (Belgium) | Holding group with three divisions: Life Sciences, Food, Chemicals |
Division | Life Sciences | Contains BioFirst Group and Natix (natural extracts for pharma and cosmetics) |
Sub-group | BioFirst Group (legal entity Biobest Group NV) | Brands: Biobest, BioWorks, Plant Products, BIOTROP. |
Platform | BIOTROP North America (created Aug 2026) | Combines BioWorks North America and BIOTROP USA; reports to Jonas Hipolito, President of BIOTROP |
Subject | BioWorks, Inc. | Horticulture, greenhouse, ornamental and specialty crops |
Results by Segment
| Segment metric (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Life Sciences revenue | 359.4 | 507.1 | 538.3 |
Food revenue | 146.6 | 151.0 | 155.2 |
Chemicals revenue | 43.3 | 39.3 | 32.4 |
Group revenue | 549.3 | 697.3 | 725.9 |
Life Sciences EBITDA | 41.2 | 102.3 | 95.4 |
Food EBITDA | 8.1 | 11.0 | 11.1 |
Chemicals EBITDA | 9.0 | 5.3 | 5.7 |
Life Sciences net result | 8.1 | 27.7 | 13.3 |
Food net result | — | 4.1 | 5.4 |
Chemicals net result | — | 2.2 | -0.3 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Derived metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Life Sciences EBITDA margin | 11.5 | 20.2 | 17.7 |
Life Sciences revenue growth YoY | 6.6 | 41.1 | 6.2 |
Life Sciences share of group revenue | 65.4 | 72.7 | 74.2 |
Food EBITDA margin | 5.5 | 7.3 | 7.2 |
Chemicals EBITDA margin | 20.8 | 13.5 | 17.6 |
Bioworks Marker Details
| BioWorks marker | Value | Source |
|---|---|---|
Revenue growth 2010 | 27% | RBJ, 5 Jul 2013 |
Revenue growth 2011 | 23% | RBJ, 5 Jul 2013 |
Revenue growth 2012 | 10% | RBJ, 5 Jul 2013 |
Growth descriptor 2018 | Double-digit annually | Western Growers profile |
Revenue target 2034 | USD 100 million | BIOTROP release, Aug 2026 |
Combined BIOTROP North America target 2034 | More than USD 260 million | BIOTROP release, Aug 2026 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 353.1 | 518.3 | 549.3 | 697.3 | 725.9 |
EBITDA (EUR Mn) | — | — | — | 116.8 | — |
Consolidated net result (EUR Mn) | 18.6 | 18.5 | 8.6 | 30.9 | 15.1 |
Net result, Floridienne share (EUR Mn) | 13.2 | 12.0 | 3.6 | 15.7 | 8.0 |
Revenue growth YoY (%) | — | 46.8 | 6.0 | 26.9 | 4.1 |
Net margin (%) | 5.3 | 3.6 | 1.6 | 4.4 | 2.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2022–FY2025)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Revenue (EUR Mn) | 337.1 | 359.4 | 507.1 | 538.3 |
EBITDA (EUR Mn) | 47.8 | 41.2 | 102.3 | 95.4 |
Net result (EUR Mn) | 13.3 | 8.1 | 27.7 | 13.3 |
EBITDA margin (%) | 14.2 | 11.5 | 20.2 | 17.7 |
Net margin (%) | 3.9 | 2.3 | 5.5 | 2.5 |
Income Statement
| Metric | H1 2022 | H1 2023 | H1 2024 | H1 2025 |
|---|---|---|---|---|
Revenue (EUR Mn) | 169.7 | 185.7 | 236.3 | 259.5 |
EBITDA (EUR Mn) | — | 28.1 | 35.7 | 34.0 |
Net result (EUR Mn) | 11.9 | 10.2 | 6.8 | -4.4 |
Region Overview
| Region | Presence | Evidence |
|---|---|---|
United States | Core market; full catalogue; national field team being expanded | Website; Feb 2026 release |
Canada | Reduced four-product catalogue; distributor network | Website |
Mexico | Distributor network | Website |
Europe | BioWorks brand launched Sep 2025; distributors purchase directly from BioWorks | New AG International |
Brazil | Destination for Trichoderma exports from Victor, announced Feb 2026 | BioWorks release |
Capital Markets
| Item | Status |
|---|---|
Credit ratings (Moody's, S&P, Fitch) | None identified |
Income Statement (Annual)
| Chartable parent metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Floridienne revenue (EUR Mn) | 353.1 | 518.3 | 549.3 | 697.3 | 725.9 |
Floridienne net result, group share (EUR Mn) | 13.2 | 12.0 | 3.6 | 15.7 | 8.0 |
Analyst Conclusions
Management guidance. There is no annual guidance. The stated targets are USD 100 million of BioWorks revenue and more than USD 260 million for the combined BIOTROP North America platform by 2034. Floridienne described the Life Sciences outlook as favourable in its FY2024 release; the FY2025 release notes currency and profitability pressure. Consensus expectations do not exist for BioWorks.
Bull case
-
Pipeline step-change. Nine launches in 2026 against a historical base of about twenty products, with BIOTROP's technology behind them, widen the catalogue into nematicides, herbicides and nutrition.
-
Manufacturing leverage. Exporting Trichoderma to Brazil and Europe turns Victor from a regional plant into a group supply node, improving fixed-cost absorption.
-
Channel and brand. Thirty years of distributor relationships and technical trust in greenhouse horticulture are hard to replicate, and they now carry more products per call.
Bear case
-
Parent constraints. Floridienne's FY2025 net result halved and H1 2025 was loss-making; investment in a small US subsidiary competes with a large Brazilian business for capital and attention.
-
Execution load. A new platform head from outside, an interim GM, a new sales director and a rapid launch schedule arrive together.
-
Competitive response. Certis, Koppert and the multinationals are all active in the same greenhouse accounts, and Floridienne itself cites tougher competition.
Catalysts and monitorables, next 12 months
-
The 90-day integrated North America strategy, due around November 2026.
-
Whether Chris Rose is confirmed as General Manager.
-
Floridienne H1 2026 and FY2026 results, especially Life Sciences EBITDA margin (17.7% in FY2025 against 20.2% in FY2024).
-
First evidence of Trichoderma export volumes.
-
EPA registrations of BIOTROP-origin products under the BioWorks label.
-
Completion of the remaining 15% BIOTROP purchase and how it is financed.
-
European registration progress under the new EMEA regulatory director.
It is a 33-year-old specialist that was sold in 2023 and now sits three levels below a Belgian listed holding company. That fact shapes everything an outside party can and cannot know about it. Its revenue, margins and headcount are undisclosed, and any figure presented for them elsewhere should be treated with suspicion.
What can be said with confidence is that the business is in the most active period of its history. Under Bill Foster it was a careful, self-funded company that found its niche in greenhouse horticulture after an early misjudgment about row crops. Under BioFirst and BIOTROP it is being asked to do something different: multiply its catalogue, sell into outdoor specialty crops, supply other continents from one New York plant, and reach USD 100 million of revenue by 2034. The 2026 launch record shows the pipeline is real. The loss of BotaniGard in 2022, and the recovery through PRINCIPLE WP, shows the organization can develop its own products when it has to.
The risks are mostly about ownership. The parent's earnings weakened in 2025, competition is intensifying, and the new North American structure places BioWorks under a leader recruited from Koppert with a mandate to integrate. The stated commitment to keep the brands and go-to-market separate is sensible, because BioWorks' value lies in grower trust and technical service, and neither survives a clumsy merger.
For a counterparty, supplier or competitor, the practical reading is this: BioWorks is a credible and growing channel into North American protected horticulture, with improving access to technology and capital, and with decisions increasingly made outside Victor. The November 2026 strategy output and the permanent GM appointment are the two events most likely to show which direction the company takes.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure and background | Source |
|---|---|---|---|
Chris Rose | Interim General Manager, BioWorks (from 24 Feb 2026) | Biologist by training; with BioWorks since 2013; previously product manager | BioWorks release; Greenhouse Grower |
Andre Cerignoni | General Manager, BIOTROP North America (from Aug 2026) | Oversees BioWorks North America and BIOTROP USA. Previously Marketing and Commercial Manager, US, at Koppert; over ten years at Koppert Brazil. MBAs from USP and FGV | BIOTROP release |
Jonas Hipolito | President, BIOTROP | Cerignoni's reporting line | BIOTROP release |
Matheus Gueratto | Head of BIOTROP USA | Built row-crop operation across 23 states with 13 registered products | BIOTROP release |
Lara Ramaekers | Vice-President, BioWorks division (Europe launch) | — | New AG International |
Jason Miller | Director of Sales and Distributor Relations Manager (from Feb 2026) | Leads North American sales strategy | BioWorks release |
Carlos E. Bográn | Director of Technical Services | — | HortiDaily, Jul 2025 |
Dr. Michael Brownbridge | Senior Technical Services Manager | — | BioWorks articles |
David Spampinato | Senior Product Manager; media contact | — | 2B Monthly; releases |
José Carvalho | Regulatory Director, BioWorks Europe | — | 2B Monthly |
Dr. Glen Stevens | R&D Associate (from Aug 2025) | Over two decades in biological control and soil health | BioWorks release |
Bill Foster | Former President and CEO | Led the company for nearly three decades; stayed through end of May 2026 for transition | BioWorks release |
Competitive Landscape
Key Competitors
| Competitor | Owner | Overlap with BioWorks | Comparable revenue |
|---|---|---|---|
Certis Biologicals | Mitsui & Co. | Closest direct rival in US greenhouse biopesticides; owns BotaniGard and Mycotrol | — |
Koppert | Private (Netherlands) | Beneficials, microbials and Trichoderma products; source of BIOTROP NA's new GM | — |
ProFarm Group (formerly Marrone Bio) | Bioceres Crop Solutions | Biofungicides and bioinsecticides in specialty crops | — |
Valent BioSciences | Sumitomo Chemical | Bt products, biostimulants | Not disclosed separately |
Bayer Crop Science (biologics) | Bayer AG | Serenade (QST 713) and others | Not disclosed separately |
BASF (biologicals) | BASF SE | Beauveria products and beneficial nematodes | Not disclosed separately |
Syngenta Biologicals | Syngenta Group | Biostimulants and biocontrols | Not disclosed separately |
Lallemand Plant Care | Lallemand Inc. (private) | Microbial biofungicides | — |
BioSafe Systems | Private (US) | Peroxide chemistries and biopesticides in greenhouse | — |
OHP | AMVAC / American Vanguard | Greenhouse and nursery specialty products including biologicals | Not disclosed separately |
SePRO | Private (US) | Greenhouse and nursery fungicides and biologicals | — |
Andermatt Group | Private (Switzerland) | Microbials, expanding in North America | — |
“—” = not publicly disclosed.
Competitor Detail
| Metric | BioWorks |
|---|---|
Growth | Not disclosed (2034 target implies sustained double-digit growth) |
Recent Developments
Entries slightly outside the window are included for context and marked.
AgroPages lists some of the 2026 items with dates a few days later than BioWorks' own releases; the BioWorks dates are used.



